Healthcare Services

In-vitro Colorectal Cancer Screening Tests Market Trends And Growth Outlook Across The 2026–2030 Forecast Period

May 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Value Of The In-vitro Colorectal Cancer Screening Tests Market Projected To Expand During 2026–2030?

The market size for in-vitro colorectal cancer screening tests has experienced significant growth in recent years. It is anticipated to expand from $1.3 billion in 2025 to $1.4 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. The historical expansion can be linked to increasing colorectal cancer incidence rates, the expansion of population screening programs, growing awareness of early cancer detection, the availability of laboratory-based diagnostic infrastructure, and improvements in biomarker identification.

The in-vitro colorectal cancer screening tests market size is projected to experience substantial expansion over the next few years. It is anticipated to grow to $1.82 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. The projected growth within this period stems from various factors, such as the increasing adoption of personalized screening strategies, a rising demand for diagnostic solutions accessible at home, the broadening of preventive healthcare programs, the expanding application of AI-assisted interpretation of results, and a heightened emphasis on cost-effective cancer screening methods. Significant trends during the forecast timeframe involve the growing popularity of non-invasive screening tests, increased deployment of multi-target stool DNA testing, greater integration of blood-based biomarker assays, the proliferation of kits for home-based sample collection, and an intensified focus on early detection among asymptomatic populations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27319&type=smp

Which Strategic Drivers Are Supporting The In-vitro Colorectal Cancer Screening Tests Market Development?

The growing occurrence of colorectal cancer is anticipated to fuel the expansion of the in vitro colorectal cancer screening tests market. Colorectal cancer is defined as a malignancy that begins in the colon or rectum, frequently evolving from precancerous polyps. This increase in prevalence stems from unhealthy lifestyle choices such as poor diet, inadequate exercise, and obesity, which heighten the risk of polyp formation and cancer progression. In vitro colorectal cancer screening tests assist in diagnosis by providing non-invasive techniques for identifying early indicators of the disease. These tests boost screening accuracy through sophisticated biomarker detection, leading to better early intervention and patient results. For instance, in February 2025, the American Cancer Society, a US-based nonprofit organization, estimated 154,270 new colorectal cancer cases, marking an increase from 152,810 cases in 2024. Thus, the escalating prevalence of colorectal cancer is a significant factor driving the growth of the in vitro colorectal cancer screening tests market.

What Key Segment Areas Are Included In The In-vitro Colorectal Cancer Screening Tests Market Assessment?

The in-vitro colorectal cancer screening tests market covered in this report is segmented –

1) By Test Type: Fecal Occult Blood Test, Stool Deoxyribonucleic Acid Test, Blood Biomarker Test, Other Test Types

2) By Imaging Type: In-vitro Confirmatory Diagnostics, Laboratory-Based Molecular Testing, Companion Diagnostic Testing, Genetic And Epigenetic Testing, Biomarker Validation Testing, Risk Stratification Assays

3) By Application: Screening, Diagnosis, Monitoring, Risk Assessment, Post-Treatment Surveillance

4) By End User: Hospitals, Diagnostic Laboratories, Outpatient Clinics, Home Care Settings, Research Institutions

Subsegments:

1) By Fecal Occult Blood Test: Guaiac Based Fecal Occult Blood Test, Immunochemical Fecal Occult Blood Test

2) By Stool Deoxyribonucleic Acid Test: Single Target Stool Deoxyribonucleic Acid Test, Multi Target Stool Deoxyribonucleic Acid Test

3) By Blood Biomarker Test: Methylated Septin 9 Deoxyribonucleic Acid Test, Circulating Tumor Deoxyribonucleic Acid Test, Protein Biomarker Based Blood Test

4) By Other Test Types: Urine Based Biomarker Test, Serum Based Biomarker Test, Breath Based Volatile Organic Compound Test

Which Trends Are Guiding The Development Of The In-vitro Colorectal Cancer Screening Tests Market?

Leading companies in the in vitro colorectal cancer screening tests market are prioritizing the development of sophisticated diagnostic solutions, such as multi-target stool DNA tests, to enhance early detection accuracy, improve patient convenience, and lower colorectal cancer mortality rates. Multi-target stool DNA tests are innovative screening tools that analyze stool samples for genetic and biochemical markers linked to colorectal cancer and precancerous lesions. For instance, in March 2025, Exact Sciences Corp., a US-based molecular diagnostics company, introduced Cologuard Plus, an improved at-home colorectal cancer screening test for average-risk adults aged 45 and older. This test integrates advanced biomarker technology, offering greater sensitivity and specificity compared to its predecessor. It employs a refined algorithm to identify DNA mutations and hemoglobin biomarkers, thereby enhancing the detection of both colorectal cancer and advanced adenomas. The Cologuard Plus test presents a non-invasive and convenient screening option that removes the need for bowel preparation or dietary restrictions, consequently boosting patient adherence to recommended screening guidelines.

Which Companies Are Engaged In The In-vitro Colorectal Cancer Screening Tests Market Environment?

Major companies operating in the in-vitro colorectal cancer screening tests market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers, Quest Diagnostics Incorporated, Roche Diagnostics International AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Natera Inc., BGI Genomics Co. Ltd., NeoGenomics Inc., Guardant Health Inc., CellMax Life Inc., Epigenomics AG, Acuamark Diagnostics Inc., Beacon Biomedical Inc., Mainz Biomed NV, Hologic Inc., Danaher Corporation, Agilent Technologies Inc.

Access The Complete In-vitro Colorectal Cancer Screening Tests Market Report:

https://www.thebusinessresearchcompany.com/report/in-vitro-colorectal-cancer-screening-tests-global-market-report

Which Region Accounts For The Highest Share Of The In-vitro Colorectal Cancer Screening Tests Market?

North America was the largest region in the in-vitro colorectal cancer screening tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-vitro colorectal cancer screening tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access In-vitro Colorectal Cancer Screening Tests Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=27319&type=smp

Browse Through More Reports Similar to the Global In-vitro Colorectal Cancer Screening Tests Market 2026, By The Business Research Company

Antifungals Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Systemic Aspergillosis And Systemic Candidiasis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/systemic-aspergillosis-and-systemic-candidiasis-global-market-report

Aspergillosis Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/aspergillosis-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795